Brief: Leap Therapeutics Announces Enrollment Completion in Randomized Controlled Part C of the DisTinGuish Study of DKN-01
02/01/2024 12:23
Jan 2 (Reuters) - Leap Therapeutics Inc LPTX.O :
* LEAP THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN
RANDOMIZED CONTROLLED PART C OF THE DISTINGUISH STUDY OF DKN-01
FOR THE TREATMENT OF GASTRIC CANCER PATIENTS
Source text for Eikon: ID:nPnbJZTBfa
Further company coverage: LPTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cypherpunk Technologies
See all newsCypherpunk Technologies Inc reports results for the quarter ended June 30 - Earnings Summary
Cypherpunk Technologies swings to Q2 profit on Zcash gains
Cypherpunk Technologies Inc expected to post a loss of 3 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Chipotle Mexican Grill, J.B. Hunt, ABM Industries
U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia